Skip to content

KLRS KLRS Return on assets

Return on assets at other companies

Eli Lilly logo
Eli LillyLLY
24.5%+10.1pp
Merck & Co. logo
Merck & Co.MRK
7.3%-8.4pp
Amgen logo
AmgenAMGN
8.6%+2.1pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
11.3%-1.2pp
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
-83.5%+2,448pp
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-51%+17.1pp

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Calculated from KLRS’s reported figures.

Based on trailing twelve months.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's return on assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's return on assets?
KLRS (KLRS) reported return on assets of -41.4% in Q1 2026.
How has KLRS's return on assets changed year-over-year?
KLRS's return on assets increased by 32.6% year-over-year, from -61.4% to -41.4%.
What is the long-term trend for KLRS's return on assets?
Over 2 years (2023 to 2025), KLRS's return on assets has grown at a -8.6% compound annual growth rate (CAGR), from -81.4% to -67.9%.
What does return on assets mean?
Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.